Toxicological Research

Korean Society of Toxicology & Korea Environmental Mutagen Society (한국독성학회)
권호 표지
DOI QR코드

DOI QR Code

c-Jun N-Terminal Kinase Signaling Inhibitors Under Development

  • Han, Sun-Young (Drug Discovery Division, Korea Research Institute of Chemical Technology)
  • Published : 2008.06.01
Download PDF
⟨ Previous Next ⟩

Abstract

Targeting protein kinases has been active area in drug discovery. The c-Jun N-terminal kinases(JNKs) have also been target for development of novel therapy in various diseases, since the roles of JNK signaling in pathological conditions were revealed in studies using jnk-deficient mice. Small molecule inhibitors and peptide inhibitors are identified for therapeutic intervention of JNK signaling pathway. SP-600125, an anthrapyrazole small molecule inhibitor for JNK with high potency and selectivity has been widely used for dissecting JNK signaling pathway. CC-401 is the first JNK inhibitor that went into clinical trial for inflammation and leukemia. Inhibitor for mixed lineage kinase (MLK), CEP-1347 also negatively regulates JNK signaling, and tried for potential use in Parkinson's disease. Cell-permeable peptide inhibitor D-JNKI-1 is being developed for the treatment of hearing loss. The current status of these JNK inhibitors and safety issue is discussed in the minireview.

Keywords

References

  1. Ahlskog, J.E. (2007). I can't get no satisfaction: still no neuroprotection for Parkinson disease. Neurology, 69, 1476-1477 https://doi.org/10.1212/01.wnl.0000277645.60799.0e
  2. Bain, J., McLauchlan, H., Elliott, M. and Cohen, P. (2003). The specificities of protein kinase inhibitors: an update. Biochem. J., 371, 199-204 https://doi.org/10.1042/BJ20021535
  3. Barr, R.K. and Bogoyevitch, M.A. (2001). The c-Jun N-terminal protein kinase family of mitogen-activated protein kinases (JNK MAPKs). Int. J. Biochem. Cell Biol., 33, 1047-1063 https://doi.org/10.1016/S1357-2725(01)00093-0
  4. Barr, R.K., Kendrick, T.S. and Bogoyevitch, M.A. (2002). Identification of the critical features of a small peptide inhibitor of JNK activity. J. Biol. Chem., 277, 10987-10997 https://doi.org/10.1074/jbc.M107565200
  5. Bennett, B.L., Sasaki, D.T., Murray, B.W., O'Leary, E.C., Sakata, S.T., Xu, W., Leisten, J.C., Motiwala, A., Pierce, S., Satoh, Y., Bhagwat, S.S., Manning, A.M. and Anderson, D.W. (2001). SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc. Natl. Acad. Sci. USA, 98, 13681-13686
  6. Bonny, C., Oberson, A., Negri, S., Sauser, C. and Schorderet, D.F. (2001). Cell-permeable peptide inhibitors of JNK: novel blockers of beta-cell death. Diabetes, 50, 77-82 https://doi.org/10.2337/diabetes.50.1.77
  7. Borsello, T. and Bonny, C. (2004). Use of cell-permeable peptides to prevent neuronal degeneration. Trends Mol. Med., 10, 239-244 https://doi.org/10.1016/j.molmed.2004.03.008
  8. Borsello, T., Clarke, P.G., Hirt, L., Vercelli, A., Repici, M., Schorderet, D.F., Bogousslavsky, J. and Bonny, C. (2003). A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia. Nat. Med., 9, 1180-1186
  9. Borsello, T. and Forloni, G. (2007). JNK signalling: a possible target to prevent neurodegeneration. Curr. Pharm. Des., 13, 1875-1886 https://doi.org/10.2174/138161207780858384
  10. Carboni, S., Boschert, U., Gaillard, P., Gotteland, J. P., Gillon, J.Y. and Vitte, P.A. (2007). AS601245, a c-Jun NH(2)-terminal kinase (JNK) inhibitor, reduces axon/dendrite damage and cognitive deficits after global cerebral ischaemia in gerbils. Br. J. Pharmacol., 153, 157-163
  11. Carboni, S., Hiver, A., Szyndralewiez, C., Gaillard, P., Gotteland, J.P. and Vitte, P.A. (2004). AS601245 (1,3-benzothiazol-2-yl (2-[[2-(3-pyridinyl) ethyl] amino]-4 pyrimidinyl) acetonitrile): a c-Jun NH2-terminal protein kinase inhibitor with neuroprotective properties. J. Pharmacol. Exp. Ther., 310, 25-32 https://doi.org/10.1124/jpet.103.064246
  12. Davis, R.J. (2000). Signal transduction by the JNK group of MAP kinases. Cell, 103, 239-252 https://doi.org/10.1016/S0092-8674(00)00116-1
  13. Ennis, B.W., Fultz, K.E., Smith, K.A., Westwick, J.K., Zhu, D., Boluro-Ajayi, M., Bilter, G.K. and Stein, B. (2005). Inhibition of tumor growth, angiogenesis, and tumor cell proliferation by a small molecule inhibitor of c-Jun N-terminal kinase. J. Pharmacol. Exp. Ther., 313, 325-332
  14. Favata, M.F., Horiuchi, K.Y., Manos, E.J., Daulerio, A.J., Stradley, D.A., Feeser, W.S., Van Dyk, D.E., Pitts, W.J., Earl, R.A., Hobbs, F., Copeland, R.A., Magolda, R.L., Scherle, P.A. and Trzaskos, J.M. (1998). Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J. Biol. Chem., 273, 18623-18632 https://doi.org/10.1074/jbc.273.29.18623
  15. Ferrandi, C., Ballerio, R., Gaillard, P., Giachetti, C., Carboni, S., Vitte, P.A., Gotteland, J.P. and Cirillo, R. (2004). Inhibition of c-Jun N-terminal kinase decreases cardiomyocyte apoptosis and infarct size after myocardial ischemia and reperfusion in anaesthetized rats. Br. J. Pharmacol., 142, 953-960 https://doi.org/10.1038/sj.bjp.0705873
  16. Flanc, R.S., Ma, F.Y., Tesch, G.H., Han, Y., Atkins, R.C., Bennett, B.L., Friedman, G.C., Fan, J.H. and Nikolic-Paterson, D.J. (2007). A pathogenic role for JNK signaling in experimental anti-GBM glomerulonephritis. Kidney Int., 72, 698-708 https://doi.org/10.1038/sj.ki.5002404
  17. Furukawa, M., Ebmeyer, J., Pak, K., Austin, D.A., Melhus, A., Webster, N.J. and Ryan, A.F. (2007). Jun N-terminal protein kinase enhances middle ear mucosal proliferation during bacterial otitis media. Infect. Immun., 75, 2562-2571 https://doi.org/10.1128/IAI.01656-06
  18. Gaillard, P., Jeanclaude-Etter, I., Ardissone, V., Arkinstall, S., Cambet, Y., Camps, M., Chabert, C., Church, D., Cirillo, R., Gretener, D., Halazy, S., Nichols, A., Szyndralewiez, C., Vitte, P.A. and Gotteland, J.P. (2005). Design and synthesis of the first generation of novel potent, selective, and in vivo active (benzothiazol-2-yl)acetonitrile inhibitors of the c-Jun N-terminal kinase. J. Med. Chem., 48, 4596-607 https://doi.org/10.1021/jm0310986
  19. Guan, Q.H., Pei, D.S., Zong, Y.Y., Xu, T.L. and Zhang, G.Y. (2006). Neuroprotection against ischemic brain injury by a small peptide inhibitor of c-Jun N-terminal kinase (JNK) via nuclear and non-nuclear pathways. Neuroscience, 139, 609-627 https://doi.org/10.1016/j.neuroscience.2005.11.067
  20. Han, Z., Boyle, D.L., Chang, L., Bennett, B., Karin, M., Yang, L., Manning, A.M. and Firestein, G.S. (2001). c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. J. Clin. Invest., 108, 73-81 https://doi.org/10.1172/JCI12466
  21. Harper, S.J. and LoGrasso, P. (2001). Signalling for survival and death in neurones: the role of stress-activated kinases, JNK and p38. Cell Signal., 13, 299-310 https://doi.org/10.1016/S0898-6568(01)00148-6
  22. Hibi, M., Lin, A., Smeal, T., Minden, A. and Karin, M. (1993). Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain. Genes. Dev., 7, 2135-2148 https://doi.org/10.1101/gad.7.11.2135
  23. Hirt, L., Badaut, J., Thevenet, J., Granziera, C., Regli, L., Maurer, F., Bonny, C. and Bogousslavsky, J. (2004). D-JNKI1, a cell-penetrating c-Jun-N-terminal kinase inhibitor, protects against cell death in severe cerebral ischemia. Stroke, 35, 1738-1743 https://doi.org/10.1161/01.STR.0000131480.03994.b1
  24. Ishii, M., Suzuki, Y., Takeshita, K., Miyao, N., Kudo, H., Hiraoka, R., Nishio, K., Sato, N., Naoki, K., Aoki, T. and Yamaguchi, K. (2004). Inhibition of c-Jun NH2-terminal kinase activity improves ischemia/reperfusion injury in rat lungs. J. Immunol., 172, 2569-2577 https://doi.org/10.4049/jimmunol.172.4.2569
  25. Kaneko, M., Saito, Y., Saito, H., Matsumoto, T., Matsuda, Y., Vaught, J.L., Dionne, C.A., Angeles, T.S., Glicksman, M.A., Neff, N.T., Rotella, D.P., Kauer, J.C., Mallamo, J.P., Hudkins, R.L. and Murakata, C. (1997). Neurotrophic 3,9- bis[(alkylthio)methyl]-and-bis(alkoxymethyl)-K-252a derivatives. J. Med. Chem., 40, 1863-1869 https://doi.org/10.1021/jm970031d
  26. Kaneto, H., Nakatani, Y., Miyatsuka, T., Kawamori, D., Matsuoka, T.A., Matsuhisa, M., Kajimoto, Y., Ichijo, H., Yamasaki, Y. and Hori, M. (2004). Possible novel therapy for diabetes with cell-permeable JNK-inhibitory peptide. Nat. Med., 10, 1128-1132 https://doi.org/10.1038/nm1111
  27. Kyriakis, J.M. and Avruch, J. (1990). pp54 microtubule-associated protein 2 kinase. A novel serine/threonine protein kinase regulated by phosphorylation and stimulated by poly-L-lysine. J. Biol. Chem., 265, 17355-17363
  28. Langston, J.W. (1996). The etiology of Parkinson's disease with emphasis on the MPTP story. Neurology, 47, S153-S160 https://doi.org/10.1212/WNL.47.6_Suppl_3.153S
  29. Lee, J.C., Kumar, S., Griswold, D.E., Underwood, D.C., Votta, B.J. and Adams, J.L. (2000). Inhibition of p38 MAP kinase as a therapeutic strategy. Immunopharmacology, 47, 185-201 https://doi.org/10.1016/S0162-3109(00)00206-X
  30. Ma, F.Y., Flanc, R.S., Tesch, G.H., Han, Y., Atkins, R.C., Bennett, B.L., Friedman, G.C., Fan, J.H. and Nikolic-Paterson, D.J. (2007). A pathogenic role for c-Jun amino-terminal kinase signaling in renal fibrosis and tubular cell apoptosis. J. Am. Soc. Nephrol., 18, 472-484 https://doi.org/10.1681/ASN.2006060604
  31. Manning, A.M. and Davis, R.J. (2003). Targeting JNK for therapeutic benefit: from junk to gold? Nat. Rev. Drug. Discov., 2, 554-565 https://doi.org/10.1038/nrd1132
  32. Manning, G., Whyte, D.B., Martinez, R., Hunter, T. and Sudarsanam, S. (2002). The protein kinase complement of the human genome. Science, 298, 1912-1934 https://doi.org/10.1126/science.1075762
  33. Maroney, A.C., Finn, J.P., Connors, T.J., Durkin, J.T., Angeles, T., Gessner, G., Xu, Z., Meyer, S.L., Savage, M.J., Greene, L.A., Scott, R.W. and Vaught, J.L. (2001). Cep-1347 (KT7515), a semisynthetic inhibitor of the mixed lineage kinase family. J. Biol. Chem., 276, 25302-25308 https://doi.org/10.1074/jbc.M011601200
  34. Maroney, A.C., Glicksman, M.A., Basma, A.N., Walton, K.M., Knight, E., Jr., Murphy, C.A., Bartlett, B.A., Finn, J.P., Angeles, T., Matsuda, Y., Neff, N.T. and Dionne, C.A. (1998). Motoneuron apoptosis is blocked by CEP-1347 (KT 7515), a novel inhibitor of the JNK signaling pathway. J. Neurosci., 18, 104-111 https://doi.org/10.1523/JNEUROSCI.18-01-00104.1998
  35. Milano, G., Morel, S., Bonny, C., Samaja, M., von Segesser, L.K., Nicod, P. and Vassalli, G. (2007). A peptide inhibitor of c-Jun NH2-terminal kinase reduces myocardial ischemiareperfusion injury and infarct size in vivo. Am. J. Physiol. Heart. Circ. Physiol., 292, H1828-H1835 https://doi.org/10.1152/ajpheart.01117.2006
  36. Parkinson Study Group (2007). Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease. Neurology, 69, 1480-1490 https://doi.org/10.1212/01.wnl.0000277648.63931.c0
  37. Parkinson Study Group (2004). The safety and tolerability of a mixed lineage kinase inhibitor (CEP-1347) in PD. Neurology, 62, 330-332 https://doi.org/10.1212/01.WNL.0000103882.56507.20
  38. Salituro, F.G., Germann, U.A., Wilson, K.P., Bemis, G.W., Fox, T. and Su, M.S. (1999). Inhibitors of p38 MAP kinase: therapeutic intervention in cytokine-mediated diseases. Curr. Med. Chem., 6, 807-823
  39. Saporito, M.S., Brown, E.M., Miller, M.S. and Carswell, S. (1999). CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine- mediated loss of nigrostriatal dopaminergic neurons In vivo. J. Pharmacol. Exp. Ther., 288, 421-427
  40. Saporito, M.S., Thomas, B.A. and Scott, R.W. (2000). MPTP activates c-Jun NH(2)-terminal kinase (JNK) and its upstream regulatory kinase MKK4 in nigrostriatal neurons in vivo. J. Neurochem., 75, 1200-1208 https://doi.org/10.1046/j.1471-4159.2000.0751200.x
  41. Schwarze, S.R., Ho, A., Vocero-Akbani, A. and Dowdy, S.F. (1999). In vivo protein transduction: delivery of a biologically active protein into the mouse. Science, 285, 1569-1572 https://doi.org/10.1126/science.285.5433.1569
  42. Suckfuell, M., Canis, M., Strieth, S., Scherer, H. and Haisch, A. (2007). Intratympanic treatment of acute acoustic trauma with a cell-permeable JNK ligand: a prospective randomized phase I/II study. Acta Otolaryngol., 127, 938-942 https://doi.org/10.1080/00016480601110212
  43. Syrkina, O.L., Quinn, D.A., Jung, W., Ouyang, B. and Hales, C.A. (2007). Inhibition of JNK activation prolongs survival after smoke inhalation from fires. Am. J. Physiol. Lung. Cell Mol. Physiol., 292, L984-L991 https://doi.org/10.1152/ajplung.00248.2006
  44. Uehara, T., Bennett, B., Sakata, S.T., Satoh, Y., Bilter, G.K., Westwick, J.K. and Brenner, D.A. (2005). JNK mediates hepatic ischemia reperfusion injury. J. Hepatol., 42, 850-859 https://doi.org/10.1016/j.jhep.2005.01.030
  45. Uehara, T., Xi Peng, X., Bennett, B., Satoh, Y., Friedman, G., Currin, R., Brenner, D.A. and Lemasters, J. (2004). c-Jun N-terminal kinase mediates hepatic injury after rat liver transplantation. Transplantation, 78, 324-332
  46. Waldmeier, P., Bozyczko-Coyne, D., Williams, M. and Vaught, J.L. (2006). Recent clinical failures in Parkinson's disease with apoptosis inhibitors underline the need for a paradigm shift in drug discovery for neurodegenerative diseases. Biochem. Pharmacol., 72, 1197-1206 https://doi.org/10.1016/j.bcp.2006.06.031
  47. Wang, J., Ruel, J., Ladrech, S., Bonny, C., van de Water, T.R. and Puel, J.L. (2007). Inhibition of the c-Jun N-terminal kinase-mediated mitochondrial cell death pathway restores auditory function in sound-exposed animals. Mol. Pharmacol., 71, 654-666 https://doi.org/10.1124/mol.106.028936
  48. Wang, J., Van De Water, T.R., Bonny, C., de Ribaupierre, F., Puel, J.L. and Zine, A. (2003). A peptide inhibitor of c-Jun N-terminal kinase protects against both aminoglycoside and acoustic trauma-induced auditory hair cell death and hearing loss. J. Neurosci., 23, 8596-8607 https://doi.org/10.1523/JNEUROSCI.23-24-08596.2003
  49. Wang, Y., Ji, H.X., Xing, S.H., Pei, D.S. and Guan, Q.H. (2007). SP600125, a selective JNK inhibitor, protects ischemic renal injury via suppressing the extrinsic pathways of apoptosis. Life Sci., 80, 2067-2075 https://doi.org/10.1016/j.lfs.2007.03.010
  50. Weston, C.R. and Davis, R.J. (2002). The JNK signal transduction pathway. Curr. Opin. Genet. Dev., 12, 14-21 https://doi.org/10.1016/S0959-437X(01)00258-1
  51. Yang, D.D., Kuan, C.Y., Whitmarsh, A.J., Rincon, M., Zheng, T.S., Davis, R.J., Rakic, P. and Flavell, R.A. (1997). Absence of excitotoxicity-induced apoptosis in the hippocampus of mice lacking the Jnk3 gene. Nature, 389, 865-870 https://doi.org/10.1038/39899